Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical data trend for Panacea Biotec's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:531349 vs VRTX, REGN, RVMD: Buyback Yield % Comparison
For the Biotechnology subindustry, Panacea Biotec's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Panacea Biotec Buyback Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Panacea Biotec's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Panacea Biotec's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Panacea Biotec (BOM:531349) has a Buyback Yield % of 0.00 as of Aug. 15, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Panacea Biotec and its competitors. According to the industry distribution chart, Panacea Biotec ranks #999999 out of 724 companies in the Biotechnology industry.
Is Panacea Biotec's Buyback Yield % too high?
Panacea Biotec's current Buyback Yield % is 0.00. Based on the distribution chart, Panacea Biotec ranks #999999 out of 724 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Panacea Biotec has a GF Score™ of 57/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Panacea Biotec's Buyback Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Panacea Biotec ranks #999999 out of 724 companies for Buyback Yield %. This places Panacea Biotec in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Panacea Biotec and its competitors. Panacea Biotec's current Buyback Yield % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Panacea Biotec stock overvalued right now?
Based on GuruFocus' analysis, Panacea Biotec (BOM:531349) is currently considered Fairly Valued. The stock's GF Value™ is ₹363.46, compared to a current price of ₹396.60 — trading 9.1% above its estimated fair value. The current Buyback Yield % is 0.00. Panacea Biotec's overall GF Score™ is 57/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Panacea Biotec (BOM:531349), the current Buyback Yield % is 0.00 as of Aug. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Panacea Biotec (BOM:531349) Overvalued in 2026?
Based on GuruFocus' analysis, Panacea Biotec stock appears to be overvalued.
The current stock price of ₹396.60 is trading 9.1% above its estimated GF Value™ of ₹363.46.
GuruFocus considers Panacea Biotec to be Fairly Valued.
Key valuation signals for BOM:531349:
Buyback Yield %: 0.00
GF Value™: ₹363.46 vs. price of ₹396.60 (9.1% above fair value)
No single metric tells the full story. See the BOM:531349 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Panacea Biotec Ltd is a Biotechnology company. It is engaged in the business of research, development, manufacturing, and marketing of branded pharmaceutical formulations, vaccines, and biopharmaceuticals. The company's operating segments include Vaccines, and Formulations. It generates maximum revenue from the Vaccines segment. The company product portfolio includes prescription products in niche therapeutic areas such as diabetes and cardiovascular management, oncology, nephrology and transplant management, osteoporosis management, gastro-intestinal care, pain management products, and pediatric immunization. The group has a business presence in India and Outside India.
57GF Score
Get the complete analysis for BOM:531349
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:531349 has been successfully added to your 
